NEW YORK, Oct. 16, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Depomed, Inc. ("Depomed") (NASDAQ:DEPO) between February 26, 2015 and August 7, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Northern District of California. To get more information go to:
http://www.zlk.com/plsra-c/depomed-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Depomed engaged in questionable practices in connection with the sales and marketing of the Company’s opioid products; (ii) the foregoing conduct, when it became known, would likely subject the Company to heightened legal and regulatory scrutiny; and (iii) as a result, Depomed’s public statements were materially false and misleading at all relevant times.
On August 7, 2017, post-market, Depomed disclosed that the Company “received a request for information from the ranking minority member of the United States Senate Committee on Homeland Security and Governmental Affairs related to the promotion of opioids” and that the Company had received “subpoenas related to opioid sales and marketing from the Office of the Attorney General of Maryland and the United States Department of Justice.”
If you suffered a loss in Depomed you have until October 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com


Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 



